$PSGR PERSHING NEVER FOLLOWs THROUGH ! ! ! ! (*) (*) On

New Post Public Reply Private Reply Replies (0) Message Board
Until2017
322
$PSGR PERSHING NEVER FOLLOWs THROUGH ! ! ! ! ( * )

( * ) On ACTUAL MINE-RELATED work !


https://www.pershingpm.com/news-media/press-r...?year=2017

https://www.pershingpm.com/news-media/press-r...ork-on-its


Excerpt : .. ( Lawyer-Language Weasel Words in RED )


PERSHING RESOURCES RECEIVES BLM PERMIT TO BEGIN WORK ON ITS NEW ENTERPRISE PROPERTY

AUGUST 10, 2017

The Company Is Cleared to Begin Road Work to Conduct a Bulk Sampling Program
RENO, NV -- (Marketwired) -- 08/10/17 --


Pershing Resources Company, Inc., (OTC PINK: PSGR) announced that it has received a BLM permit for its plan to clear an access road to begin a bulk sampling program on its New Enterprise Project site near Kingman Arizona. The permit will be in effect for a period of two years and specifies bulk sampling as the primary purpose for the road clearing. The primary target of the program will be a pre-existing ore stockpile that has been estimated to contain between eight to ten thousand tons of unprocessed ore. The stockpile has been sampled and been determined to contain commercially viable levels of, copper, gold, lead, silver and, zinc.

The Company has hired an outside contractor with road building and site operations expertise and is presently reviewing logistics for a project plan to transport the ore and set up an offsite crushing operation on private land near the mine site. The Company will begin work on an access road on the site in the next 60 days and plans to then begin removing material for processing after its Geologic Team has completed the field work on a planned Phase One mapping and sampling program to determine inferred mineral reserves on the property later this fall. The New Enterprise ore stockpile was sampled by the previous holder of the claims in 2010 and returned commercial values of silver and gold.

The Company plans to have an ore characterization study performed by an independent lab to confirm and document the most efficient extraction process for the sulfide ore type which is prevalent on the site. The Company plans to move forward with its bulk sampling program as soon as funding is in place.

Pershing Resources' CEO, Steve Plumb stated, "We are very pleased that the BLM has given us a greenlight so we can begin the next stage of our development plan for the New Enterprise. We are looking forward to making substantial progress in the coming months. "

Updates on Pershing Resources' New Enterprise can be followed at: http://www.pershingpm.com/projects/the-new-en...se-project

= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =


(1) The Company is quite definite about what is to "begin" happening !
(1a) IF WORK ACTUALLY DID BEGIN in the next 60 days then there would
. . . actually be actual work progress to actually report . .. Snicker !

(2) I have not seen any "updates", have you ? .. It has been six months ! ! ! !

(3) Have the incompetent & irresponsible Managers(?) and Directors(?)
of this Company(?) ever ever ever made a follow-up report to "promised"
ACTUAL MINING-RELATED WORK, ever ? ! ? ! ?

= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =


We are examining work that was indicated as coming, or "promised
work" if you will. . POINT BEING THAT PERSHING NEVER FOLLOWS-
THROUGH ON
( actual mining-related ) PROMISED WORK ! ! ! !



There is a point to this . .. Coming in the next post .



Until2017







Pershing Resources Company Inc. (PSGR) Stock Research Links

PSGR Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading